StockNews.com Initiates Coverage on Regulus Therapeutics (NASDAQ:RGLS)

Stock analysts at StockNews.com started coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a research report issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Regulus Therapeutics in a research report on Monday, May 9th.

Regulus Therapeutics stock opened at $0.26 on Wednesday. Regulus Therapeutics has a 1 year low of $0.16 and a 1 year high of $1.05. The firm has a 50 day moving average price of $0.24 and a 200 day moving average price of $0.27. The company has a market cap of $37.96 million, a price-to-earnings ratio of -0.90 and a beta of 2.18. The company has a debt-to-equity ratio of 0.07, a quick ratio of 12.32 and a current ratio of 12.32.

Regulus Therapeutics (NASDAQ:RGLS – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). During the same quarter last year, the business posted ($0.08) earnings per share. Sell-side analysts predict that Regulus Therapeutics will post -0.22 EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. acquired a new stake in shares of Regulus Therapeutics during the first quarter worth approximately $8,656,000. DAFNA Capital Management LLC bought a new position in shares of Regulus Therapeutics in the fourth quarter valued at approximately $1,750,000. Asymmetry Capital Management L.P. raised its position in shares of Regulus Therapeutics by 94.9% in the fourth quarter. Asymmetry Capital Management L.P. now owns 2,731,044 shares of the biopharmaceutical company’s stock valued at $860,000 after purchasing an additional 1,329,553 shares during the period. Vanguard Group Inc. raised its position in shares of Regulus Therapeutics by 21.4% in the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 648,121 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Regulus Therapeutics by 498.2% in the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 111,100 shares during the period. Institutional investors own 47.06% of the company’s stock.

Regulus Therapeutics Company Profile (Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Read More